$23.72
6.08%
Nasdaq, Nov 21, 10:12 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US60770K1079
Symbol
MRNA

Moderna Stock price

$23.72
-3.77 13.71% 1M
-2.08 8.06% 6M
-17.86 42.95% YTD
-14.53 37.99% 1Y
-153.03 86.58% 3Y
-77.31 76.52% 5Y
+5.12 27.53% 10Y
+5.12 27.53% 20Y
Nasdaq, Closing price Fri, Nov 21 2025
+1.36 6.08%
ISIN
US60770K1079
Symbol
MRNA
Industry

New AI Insights on Moderna Insights AI Insights on Moderna

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$9.3b
Enterprise Value
$4.8b
Net debt
positive
Cash
$4.5b
Shares outstanding
391.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.2 | 4.8
EV/Sales
2.2 | 2.5
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
77.1%
Return on Equity
-32.7%
ROCE
-29.9%
ROIC
-43.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.2b | $1.9b
EBITDA
$-2.9b | $-4.0b
EBIT
$-3.1b | $-4.2b
Net Income
$-3.1b | $-3.9b
Free Cash Flow
$-2.7b
Growth (TTM | estimate)
Revenue
-56.1% | -40.1%
EBITDA
-61.6% | -21.4%
EBIT
-46.3% | -20.8%
Net Income
-40.1% | -9.3%
Free Cash Flow
32.7%
Margin (TTM | estimate)
Gross
63.5%
EBITDA
-130.6% | -204.4%
EBIT
-139.9%
Net
-139.6% | -201.0%
Free Cash Flow
-119.3%
More
EPS
$-8.0
FCF per Share
$-6.8
Short interest
19.8%
Employees
6k
Rev per Employee
$560.0k
Show more

Is Moderna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,052 stocks worldwide.

Moderna Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Moderna forecast:

4x Buy
13%
18x Hold
60%
8x Sell
27%

Analyst Opinions

30 Analysts have issued a Moderna forecast:

Buy
13%
Hold
60%
Sell
27%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,232 2,232
56% 56%
100%
- Direct Costs 815 815
26% 26%
37%
1,417 1,417
64% 64%
63%
- Selling and Administrative Expenses 1,061 1,061
18% 18%
48%
- Research and Development Expense 3,479 3,479
28% 28%
156%
-2,915 -2,915
62% 62%
-131%
- Depreciation and Amortization 208 208
37% 37%
9%
EBIT (Operating Income) EBIT -3,123 -3,123
46% 46%
-140%
Net Profit -3,116 -3,116
40% 40%
-140%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Neutral
Reuters
4 days ago
Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue growth next year.
Neutral
Accesswire
4 days ago
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028 CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it has closed a five-year term loan facility for up to $1.5 billion of capital fro...
Neutral
Accesswire
4 days ago
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028 Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 exp...
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,800
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today